Nachrichten zur Assembly Biosciences Inc. Aktie

Assembly Bio Commences Early-Stage Study of Drug to Treat Hepatitis B Viral Infection

Assembly Biosciences, Inc. (NASDAQ: ASMB) today announced Initiation of Phase 1b clinical study of its drug candidate ABI-H3733 for Chronic…

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Form 8-K ASSEMBLY BIOSCIENCES, For: May 25

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Assembly Biosciences GAAP EPS of -$0.48

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 10-Q ASSEMBLY BIOSCIENCES, For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Assembly Biosciences stock price target cut to $12 from $15 at Truist

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

Insiderhandel: Chief Operating Officer verkauft Aktien von Assembly Biosciences im Wert von 10.363$

Okazaki, Jason A. - Vorstand - Tag der Transaktion: 2022-03-28...…

Assembly Biosciences GAAP EPS of -$3.00 misses by $0.90, revenue of $6.25M beats by $0.09M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Form 8-K ASSEMBLY BIOSCIENCES, For: Feb 01

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 03, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Assembly Biosciences (ASMB) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®

HBV core inhibitor data will be highlighted in one oral and two poster presentations, including one late breaking HBV core…

Assembly Biosciences and Antios ink clinical collaboration agreement

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq:…

Assembly Bio Announces October Conference Participation

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Mid-Day Market Update: Crude Oil Jumps Over 2%; Assembly Biosciences Shares Plunge

Midway through trading Thursday, the Dow traded up 0.42% to 35,461.47 while the NASDAQ rose 0.39% to 15,369.38. The S&P…

Assembly Biosciences Shares Drop After Discontinuing Development of a Treatment

Assembly Biosciences Shares Drop After Discontinuing Development of a Treatment...…

The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab

Heres a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week…

Assembly Bio Stock Tumbles On Discontinuation Of Hepatitis B Trial

ASSEMBLY BIOSCIENCES, INC.: 8-K Report

8-K...…

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Insiderhandel: CEO and President verkauft Aktien von Assembly Biosciences im Wert von 43.781$

Mchutchison, John G. - Vorstand - Tag der Transaktion: 2021-08-09...…

Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.06% and -100.00%, respectively, for the quarter ended June 2021. Do…

Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

ASSEMBLY BIOSCIENCES, INC.: 8-K Report

8-K...…

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Assembly Bio presents data from HBV core inhibitor programs at EASL 2021

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

ASSEMBLY BIOSCIENCES, INC.: 8-K Report

8-K...…

ASSEMBLY BIOSCIENCES, INC.: 8-K Report

8-K...…

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., May 07, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. Do…

ASSEMBLY BIOSCIENCES, INC.: 10-Q Report

10-Q...…

ASSEMBLY BIOSCIENCES, INC.: 8-K Report

Q1 EARNINGS RELEASE 8-K...…

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology…

Assembly Biosciences (ASMB) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Assembly Biosciences, Inc. (ASMB) CEO on Hepatitis B Program Update Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

ASSEMBLY BIOSCIENCES, INC.: 8-K Report

8-K...…

Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection

Assembly Bio, Arbutus Bio commence trial of triple combo therapy in hepatitis B

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus

Trial will evaluate Assemblys core inhibitor candidate, vebicorvir, with Arbutus RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy...…